Pfizer Inc (PFE)
26.28
-0.04
(-0.15%)
USD |
NYSE |
Apr 24, 16:00
26.20
-0.08
(-0.30%)
After-Hours: 18:12
Pfizer Research and Development Expense (TTM): 10.68B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.68B |
| September 30, 2023 | 11.48B |
| June 30, 2023 | 11.46B |
| March 31, 2023 | 11.63B |
| December 31, 2022 | 11.43B |
| September 30, 2022 | 11.26B |
| June 30, 2022 | 11.24B |
| March 31, 2022 | 10.67B |
| December 31, 2021 | 10.36B |
| September 30, 2021 | 10.26B |
| June 30, 2021 | 9.876B |
| March 31, 2021 | 9.715B |
| December 31, 2020 | 9.393B |
| September 30, 2020 | 8.608B |
| June 30, 2020 | 8.591B |
| March 31, 2020 | 8.355B |
| December 31, 2019 | 8.386B |
| September 30, 2019 | 8.039B |
| June 30, 2019 | 7.764B |
| March 31, 2019 | 7.719B |
| December 31, 2018 | 7.759B |
| September 30, 2018 | 7.864B |
| June 30, 2018 | 7.721B |
| March 31, 2018 | 7.711B |
| December 31, 2017 | 7.684B |
| Date | Value |
|---|---|
| September 30, 2017 | 7.90B |
| June 30, 2017 | 7.916B |
| March 31, 2017 | 7.877B |
| December 31, 2016 | 7.892B |
| September 30, 2016 | 7.708B |
| June 30, 2016 | 7.549B |
| March 31, 2016 | 7.535B |
| December 31, 2015 | 7.689B |
| September 30, 2015 | 8.55B |
| June 30, 2015 | 8.63B |
| March 31, 2015 | 8.655B |
| December 31, 2014 | 8.393B |
| September 30, 2014 | 6.995B |
| June 30, 2014 | 6.82B |
| March 31, 2014 | 6.591B |
| December 31, 2013 | 6.678B |
| September 30, 2013 | 6.888B |
| June 30, 2013 | 7.148B |
| March 31, 2013 | 7.218B |
| December 31, 2012 | 7.57B |
| September 30, 2012 | 7.743B |
| June 30, 2012 | 8.032B |
| March 31, 2012 | 8.663B |
| December 31, 2011 | 8.692B |
| September 30, 2011 | 9.391B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
7.764B
Minimum
Jun 2019
11.63B
Maximum
Mar 2023
9.957B
Average
10.26B
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 4.784B |
| Gilead Sciences Inc | 5.719B |
| Johnson & Johnson | 15.30B |
| Viking Therapeutics Inc | 63.81M |
| Moderna Inc | 4.845B |